The Genentech therapy has been approved for routine prophylaxis in adults and children with or without factor VIII inhibitors.
The National Hemophilia Foundation (NHF) is pleased to announce the 2018 NHF-Shire Clinical Fellowship award recipients: Hanny Al-Samkari, MD, of Boston Hemophilia Center/Massachusetts General Hosp
HANDI hopes that you find these resources to be helpful and informative as you or a family member face a major life transition.
Watch this video to learn how copay accumulator adjustments affect patients requiring specialty medications with no generic alternatives.
Provide your input today and you will be helping to guide the critical future of inhibitor research.
Investigators study early risk factors and prevention of cardiovascular disease in children and young adults with hemophilia.
By accessing this activity healthcare providers will increase their knowledge of the potential role of gene therapy to address challenges in current hemophilia treatment.
Bayer received FDA approval for new extended half-life hemophilia A product for patients 12 yrs and older.
The new vial size will reduce the reconstitution time that was needed to prepare multiple vials for a similar dose.
The therapy is for people with severe and moderately severe hemophilia B.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car